News | Cardiovascular Education | September 14, 2022

Late-breaking Clinical Trial presentations announced for The VEINS and VIVA Conference

Details on late-breaking clinical trials to be presented during The VEINS (Venous Endovascular INterventional Strategies) and VIVA (Vascular InterVentional Advances) Annual Conference have been announced. Leading physicians and researchers will present results from 21 clinical trials, from Monday, October 31, to Wednesday, November 2, at Wynn Las Vegas.

Details on late-breaking clinical trials to be presented during The VEINS (Venous Endovascular INterventional Strategies) and VIVA  (Vascular InterVentional Advances) Annual Conference, Oct. 30-Nov. 3, 2022, have been announced.

September 14, 2022 — Details on late-breaking clinical trials to be presented during The VEINS (Venous Endovascular INterventional Strategies) and VIVA  (Vascular InterVentional Advances) Annual Conference have been announced. Leading physicians and researchers will present results from 21 clinical trials, from Monday, October 31, to Wednesday, November 2, at Wynn Las Vegas.

The VEINS and VIVA bring together a global, multispecialty faculty to present a variety of talks and live case presentations from clinical centers around the world. Attendees for both events include an audience of interventional cardiologists, interventional radiologists, vascular surgeons, and endovascular medicine specialists.

The VEINS 2022, October 30-31, is a comprehensive education symposium focused on the diagnosis, intervention, and management of venous disorders. The Conference will delve into PE, superficial and deep vein disease, pelvic vein disease, dialysis, and medical management. Those in attendance will explore key clinical topics, current practice trends, and get a glimpse of what’s next in venous disease care.

VIVA22, October 31-November 3, is a vascular education symposium that emphasizes innovation and multidisciplinary learning. The milestone conference will mark VIVA's 20th anniversary as a premier educational event for endovascular specialists. VIVA22 will continue to define innovation in vascular medicine and intervention, featuring a world-renowned, multispecialty faculty; extended concurrent and pre-course sessions; state-of-the-art technology, according to Conference planners. The VIVA Foundation is a not-for-profit organization committed to improving patient outcomes by advancing the field of vascular medicine and intervention through collaborative education, advocacy, and targeted research.

Late-Breaking Clinical Trial results to be released, with each presentation to include Q&A from a multidisciplinary panel, are listed alphabetically by trial name.

Late-breaking Clinical Trials during THE VEINS Conference:

ABRE Study: Clinical Outcomes by Initial Clinical Presentation Through 36 Months: Stephen A. Black, MD

Decreased ICU Cost for Iliofemoral DVT Patients Treated with Thrombectomy: John Filtes, MD

First-in-Human Study Results with Amplifi Vein Dilation System Treatment: Surendra Shenoy, MD, PhD

Improvement in Clinical and Echo Parameters After Computer-Aided Mechanical Aspiration Thrombectomy for Treatment of Acute Pulmonary Embolism: Elias Iliadis, MD

In-Hospital and 30-day Outcomes from the Fully-Enrolled, Multicenter, Prospective CLOUT Registry: David Dexter, MD

Propensity-Score Matched Analysis of Early Clinical Outcomes From the CLOUT and ATTRACT Studies: Steven Abramowitz, MD

Late-breaking Clinical Trials during VIVA22 include:

3-Year Results of the GORE VIABAHN Stent-Graft in the Superficial Femoral Artery for In-Stent Restenosis: Peter Soukas, MD

12-Month Results from a Prospective Study of the Rotarex Atherectomy and Thrombectomy Catheter System: Michael Lichtenberg, MD

36-Month Outcomes for the BioMimics Stent in Longer Lesions: A Subgroup Analysis of the MIMICS-3D EU Registry: Michael Lichtenberg, MD

A Patient-Level, Propensity-Adjusted Comparison of Drug-Coated Balloons vs Bare Metal Stents in Femoropopliteal Lesions: 3-Year Results in Prospective, Multicenter Studies: Mehdi Shishehbor, DO, MPH, PhD

A Registry-Based Study of Paclitaxel Drug-Coated Balloon Angioplasty for the Treatment of In-Stent Restenosis of the Femoral-Popliteal Artery: Daniel Bertges, MD

Cross-Seal IDE Trial: Prospective, Multi-Center, Single Arm Study of the Cross-Seal Suture-Mediated Vascular Closure Device System: Prakash Krishnan, MD

ELEGANCE: Increasing Diversity in Peripheral Artery Disease Trials: Maureen Kohi, MD

Intermediate Term (24-Month) Results of the TRANSCEND Study Comparing a Next-Generation Paclitaxel Drug-Coated Balloon (SurVeil DCB) to IN.PACT Admiral DCB in the Treatment of Femoropopliteal Artery Disease: Kenneth Rosenfield, MD

Intravascular Lithotripsy for the Treatment of Peripheral Artery Calcification: Results from the Disrupt PAD III Observational Study: Ehrin Armstrong, MD

Percutaneous Bypass for Treatment of Femoropopliteal Disease: 1-Year Outcomes of the DETOUR-2 Study: Sean Lyden, MD

Periprocedural and Patient-Reported Quality of Life Outcomes After Computer-Aided Mechanical Aspiration Thrombectomy for the Treatment of Acute Pulmonary Embolism: Interim Analysis of the STRIKE-PE Study: Ido Weinberg, MD

Revascularization Therapy for Femoropopliteal Disease With a Novel Intra-Arterial Stent Graft: 12-Month Results of the TORUS-2 Study: Ehrin Armstrong, MD

Safety and Performance of the Indigo Aspiration System for the Treatment of Lower Extremity Acute Limb Ischemia: Interim Analysis of the STRIDE Study: Thomas Maldonado, MD

The AFX2 Anatomically Fixated Endograft Has Similar Outcomes to Commercially Available Proximally Fixated Endografts: 5-Year Results of the LEOPARD Trial: Christopher Kwolek, MD, MBA

Utility of Sirolimus Drug-Eluting Balloons in the Treatment of Complex Below-the-Knee Atherosclerotic Disease in Patients With Chronic Limb-Threatening Ischemia – 24-Month Results From the PRESTIGE Study: Tjun Tang, MD

For additional information on Conference programming:

https://viva-foundation.org/veins-programming

More information on VIVA22


Related Content

News | Cardiovascular Education

August 29, 2022 — ­The US Preventive Services Task Force (USPSTF) has issued a Recommendation Statement, relating to ...

Home August 29, 2022
Home
News | Cardiovascular Education

August 11, 2022 — The Heart Rhythm Society (HRS) announced the full lineup of speakers and sessions for its first annual ...

Home August 11, 2022
Home
Feature | Cardiovascular Education | by Tristan Pendergrass

Driven by an aging population and a growing incidence of heart disease, the cardiac device industry is seeing ...

Home June 27, 2022
Home
News | Cardiovascular Education
April 4, 2022 – The American College of Cardiology's Evolving Practice of Cardiovascular Precision Medicine course on ...
Home April 04, 2022
Home
News | Cardiovascular Education
March 1, 2022 – To meet the growing industry demand for highly trained clinical professionals specializing in cardiac ...
Home March 01, 2022
Home
News | Cardiovascular Education

February 17, 2022 – Mytonomy, known for raising the bar in video-based patient-engagement content and platform, is ...

Home February 17, 2022
Home
News | Cardiovascular Education | Dave Fornell, Editor

All medical conferences moved to a virtual meeting format due to COVID-19 this year, and there has been apprehension ...

Home August 14, 2020
Home
Videos | Cardiovascular Education

Andrew D. Krahn, M.D., FHRS, head of the division of cardiology at St. Paul’s Hospital, professor of medicine at the ...

Home May 22, 2020
Home
Feature | Cardiovascular Education | Judy Haluka, RCIS, EMT

The treatment of all patients in distress with significant symptoms begins with the basics, and pediatric tachycardia is ...

Home May 02, 2019
Home
Technology | Cardiovascular Education

March 26, 2019 — Level Ex, creators of medical video games for physicians, expanded into cardiology with the launch of ...

Home March 26, 2019
Home
Subscribe Now